Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 12, 2022

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic HNSCC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
J. Clin. Oncol 2022 Mar 25;[EPub Ahead of Print], B Burtness, D Rischin, R Greil, D Soulières, M Tahara, G de Castro, A Psyrri, I Brana, N Basté, P Neupane, Å Bratland, T Fuereder, BGM Hughes, R Mesia, N Ngamphaiboon, T Rordorf, WZ Wan Ishak, J Ge, RF Swaby, B Gumuscu, K Harrington

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading